| FDA approval | ✓ FDA-approved (NDA) | ✓ FDA-approved (ANDA) | ✗ Not FDA-approved (compliance-based exception only) |
|---|
| Active ingredient identity | Original molecule (pharma-manufactured) | Bioequivalent — same molecule, lower cost | Same molecule — но pharmacy-prepared, не bioequivalence-tested |
|---|
| Cost (monthly cash) | $968-$1349/mo (list) | N/A for GLP-1 (no generic semaglutide/tirzepatide yet — patents into 2031+) | $150-$500/mo typically |
|---|
| Insurance coverage | Most plans cover diabetes use; weight loss highly plan-dependent | N/A для GLP-1 | Almost never covered — cash-pay route |
|---|
| Regulation | FDA NDA pathway (full clinical trials) | FDA ANDA (bioequivalence demonstrated) | State boards of pharmacy + FDA 503A/503B framework |
|---|
| Quality control | GMP manufacturing + lot-level FDA oversight | GMP manufacturing + FDA oversight | Variable — pharmacy-specific. Reputable pharmacies use 503B GMP standards. |
|---|
| Availability | Direct from manufacturer + pharmacies. Historical shortages of semaglutide + tirzepatide resolved 2024. | Not available для GLP-1 | Available, но FDA tightened access после shortage resolution. Now requires medical-necessity exception. |
|---|
| Dose options | Fixed pen doses per FDA label | N/A | Flexible — pharmacy can compound custom doses |
|---|
| Sterility testing | Lot-level by manufacturer | Lot-level by manufacturer | Required by 503A/503B regulations; verify the certificate of analysis (COA) |
|---|
| Legal exposure for patient | None | None | None для patient если prescriber documents medical-necessity exception properly |
|---|